


This article was downloaded by: [University of Aberdeen]

On: 04 October 2014, At: 15:09

Publisher: Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Journal of Asian Natural Products Research

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/ganp20>

Two new furostanol saponins from *Aspidistra typica*

Jiang-Ming Cui^{a b}, Li-Ping Kang^{b c}, He-Shui Yu^{b c}, Yang Zhao^b,
Cheng-Qi Xiong^b, Chao Liu^b & Bai-Ping Ma^b

^a School of Pharmaceutical Sciences, Central South University, Changsha, 410013, China

^b Department of Biotechnology, Beijing Institute of Radiation Medicine, Beijing, 100850, China

^c Graduate School of Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, China

Published online: 16 May 2013.

To cite this article: Jiang-Ming Cui, Li-Ping Kang, He-Shui Yu, Yang Zhao, Cheng-Qi Xiong, Chao Liu & Bai-Ping Ma (2013) Two new furostanol saponins from *Aspidistra typica*, *Journal of Asian Natural Products Research*, 15:5, 525-531, DOI: [10.1080/10286020.2013.787991](https://doi.org/10.1080/10286020.2013.787991)

To link to this article: <http://dx.doi.org/10.1080/10286020.2013.787991>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms &

Conditions of access and use can be found at <http://www.tandfonline.com/page/terms-and-conditions>

Two new furostanol saponins from *Aspidistra typica*

Jiang-Ming Cui^{ab}, Li-Ping Kang^{bc}, He-Shui Yu^{bc}, Yang Zhao^b, Cheng-Qi Xiong^b,
Chao Liu^{b*} and Bai-Ping Ma^{b*}

^aSchool of Pharmaceutical Sciences, Central South University, Changsha 410013, China;

^bDepartment of Biotechnology, Beijing Institute of Radiation Medicine, Beijing 100850, China;

^cGraduate School of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China

(Received 27 December 2012; final version received 17 March 2013)

Two new furostanol saponins (**1** and **2**), along with one known saponin (**3**), were obtained from the rhizomes of *Aspidistra typica* Baill. Their structures were elucidated as (2*R*)-26-*O*-β-D-glucopyranosyl-furost-5-ene-12-one-3β,22α,26-triol-3-*O*-β-D-glucopyranosyl-(1 → 2)-[β-D-xylopyranosyl-(1 → 3)]-β-D-glucopyranosyl-(1 → 4)-β-D-galactopyranoside (**1**, typaspidoside A), (2*S*)-26-*O*-β-D-glucopyranosyl-furost-5-ene-12-one-3β,22α,26-triol-3-*O*-β-D-glucopyranosyl-(1 → 2)-[β-D-xylopyranosyl-(1 → 3)]-β-D-glucopyranosyl-(1 → 4)-β-D-galactopyranoside (**2**, 2*S*S-typaspidoside A), and timosaponin H₁ (**3**), based on the integrative spectroscopic analysis of 1D- and 2D-NMR experiments, ESI-MS data and chemical evidence. The investigation on the chemical components of this plant is reported for the first time.

Keywords: *Aspidistra typica*; furostanol saponins; typaspidoside A; 2*S*S-typaspidoside A

1. Introduction

The family Convallariaceae, mainly consisting of *Speirantha*, *Convallaria*, *Theropogon*, *Rohdea*, *Reineckia*, *Aspidistra*, and *Tupistra*, is known for its rich source of steroidal saponins. To our best knowledge, many steroidal saponins with the characterized skeleton of polyhydroxylated A/B ring were reported from Convallariaceae [1]. *Aspidistra typica* Baill. is a perennial herbaceous plant which belongs to the genus *Aspidistra* with approximately 50 species [2]. It is being used to treat fractures, congestion, and snakebite as a folk herbal medicine. However, no more than 25 compounds were isolated from the genus *Aspidistra* [3–12]. With a purpose of searching for steroidal saponins with novel structures and bioactivities, studies on the constituents of *A. typica* were carried out. It was described here that two new steroidal saponins, along with one known compound,

were isolated from the dried rhizomes of *A. typica*, and their structures were characterized by 1D-NMR (¹H and ¹³C NMR), 2D-NMR (correlated spectrometry (COSY), HSQC, and heteronuclear multiple bond coherence (HMBC)), MS data, and chemical evidence.

2. Results and discussion

The ethanol extracts of *A. typica* were extracted with *n*-BuOH to obtain the total saponins. The *n*-BuOH fraction was chromatographed on silica gel, MCI CHP20/P50, and octadecylsilyl (ODS) silica gel columns, and finally purified by semi-preparative high performance liquid chromatography (HPLC) to give three compounds **1–3** (Figure 1). By comparing the NMR and MS data with those in the literature [13], compound **3** was determined as timosaponin H₁.

*Corresponding authors. Email: liuchao9588@sina.com; mabaiping@sina.com




Figure 1. The structures of compounds 1–3.

Compound **1** was isolated as a white amorphous solid, which showed positive color reaction in Liebermann–Burchard and Ehrlich reagent tests, indicating a furostanol saponin. Its molecular formula C₅₆H₉₀O₂₉ was deduced from the pseudomolecular ion peak at m/z 1225.5457 [M–H][–] in the HR-ESI-MS, which was further supported by the ¹H and ¹³C NMR data. The existence of four hexose units and one pentose unit was proved by the fragment ion peaks in the negative-ion ESI-MS at m/z 1093 [M–H–132][–], 1063 [M–H–162][–], 931 [M–H–132–162][–], 751 [M–H–132–162–162–18][–], 589 [M–H–132–162–162–162–18][–], and 427 [M–H–132–162–162–162–18–162][–]. The sugar moieties consisting of one D-galactose, three D-glucoses, and one D-xylose were established by acid hydrolysis experiment. Five anomeric proton signals at δ 4.80 (d, $J = 7.8$ Hz, H-1 of Glc3), 4.86 (d, $J = 7.8$ Hz, H-1 of Gal), 5.18 (d, $J = 8.4$ Hz, H-1 of Glc1), 5.22

(d, $J = 7.8$ Hz, H-1 of Xyl), and 5.57 (d, $J = 7.8$ Hz, H-1 of Glc2) were observed, and the β -configuration of each sugar residue was confirmed by the $J_{1,2}$ value (>7.0 Hz) in the ¹H NMR spectrum [14]. Meanwhile, five anomeric carbon signals at δ 105.0 (C-1 of Glc3), 102.8 (C-1 of Gal), 105.2 (C-1 of Glc1), 105.0 (C-1 of Xyl), and 104.9 (C-1 of Glc2) were assigned in the HSQC spectrum.

In the ¹H NMR spectrum, two singlet signals at δ 1.14 (3H, s, CH₃-18) and 0.89 (3H, s, CH₃-19) and two doublet signals at δ 1.53 (3H, d, $J = 6.6$ Hz, CH₃-21) and 0.97 (3H, d, $J = 7.2$ Hz, CH₃-27) were suggested to be characteristic steroidal methyls. A series of typical carbon signals at δ 140.8, 121.4, 110.8, and 212.8 revealed the presence of $\Delta^{5(6)}$, α -orientation of 22-OH [15], and one ketonic carbonyl group in the furostanol skeleton. The ketonic carbonyl group at C-12 was confirmed by the HMBC correlations between C-12 at δ 212.8 and H_a-11 at δ




Figure 2. Key HMBC correlations for compound **1**.

2.27, H_b-11 at δ 2.51, H-18 at δ 1.14, and H-17 at δ 2.93 (Figure 2). According to the chemical shift difference between two proton signals of C-26 ($\Delta_{ab} = 0.34$), the C-25 configuration was recognized as *R* [16]. By comparing the NMR data with those in the literature, aglycone of **1** was elucidated as (25*R*)-furost-5-ene-3 β ,22 α ,26-triol-12-one [17,18].

Connections among sugars and the sugar linkage sites to the aglycone were validated by the HMBC correlations of H-1 of Glc3 at δ 4.80 with C-26 at δ 75.3, H-1 of Xyl at δ 5.22 with C-3 of Glc1 at δ 86.8, H-1 of Glc2 at δ 5.57 with C-2 of Glc1 at δ 81.4, H-1 of Glc1 at δ 5.18 with C-4 of Gal at δ 79.9, and H-1 of Gal at δ 4.86 with C-3 at δ 77.9 (C-3) (Figure 2). Finally, all analyses above led us to determine the structure of **1** as (25*R*)-26-*O*- β -D-glucopyranosyl-furost-5-en-12-one-3 β ,22 α ,26-triol-3-*O*- β -D-glucopyranosyl-(1 \rightarrow 2)-[β -D-xylopyranosyl-(1 \rightarrow 3)]- β -D-glucopyranosyl-(1 \rightarrow 4)- β -D-galactopyranoside, named tyaspidoside A.

Compound **2** was obtained as a white amorphous powder. It was also suggested to be a furostanol saponin based on its

positive Liebermann–Burchard and Ehrlich reactions. The HR-ESI-MS showed a quasi-molecular ion peak at m/z 1225.5453 $[M-H]^-$, corresponding to the molecular formula C₅₆H₉₀O₂₉. All the MS and NMR data of **1** and **2** were closely similar, except that the chemical shifts of two protons of C-26 were slightly but distinctly different between **1** and **2** in the ¹H NMR spectrum. The signals at δ 4.07 (1H, 26-H_a) and 3.49 (1H, 26-H_b) of **2** were instead of the signals at δ 3.94 (1H, 26-H_a) and 3.60 (1H, 26-H_b) of **1**. So the C-25 configuration of **2** should be *S* [16]. Accordingly, the structure of **2** was determined as (25*S*)-26-*O*- β -D-glucopyranosyl-furost-5-en-12-one-3 β ,22 α ,26-triol-3-*O*- β -D-glucopyranosyl-(1 \rightarrow 2)-[β -D-xylopyranosyl-(1 \rightarrow 3)]- β -D-glucopyranosyl-(1 \rightarrow 4)- β -D-galactopyranoside, an epimer of **1**, named 25*S*-tyaspidoside A.

3. Experimental

3.1 General experimental procedures

Optical rotations were measured with a Perkin-Elmer 343 polarimeter (Perkin-Elmer, Waltham, MA, USA). IR spectra were recorded on a Vertex 70 spectrometer (Bruker Optics, Billerica, Germany). The

NMR spectra were recorded with a Varian UNITY INOVA 600 (599.8 MHz for ^1H NMR and 150.8 MHz for ^{13}C NMR; Palo Alto, CA, USA), with tetramethylsilane as internal standard and pyridine- d_5 as solvent. The HR-ESI-MS was recorded on Synapt MS system (Waters Corporation, Milford, MA, USA). Gas chromatographic analyses were carried out by using an Agilent 6890 system equipped with a 5973 mass spectrograph detector and an HP-5 capillary column (30 m \times 0.25 mm \times 0.25 μm ; Agilent, Milford, MA, USA). MCI CHP20/P50 (Mitsubishi Chemical, Tokyo, Japan), ODS silica gel (120 \AA , 50 μm , YMC, Kyoto, Japan), and silica gel H (Qingdao marine Chemical, Qingdao, China) were used for chromatography. Thin layer chromatography was carried out on silica gel 60 plates (Merck, Darmstadt, Germany). HPLC (Agilent Technologies, Santa Clara, CA, USA) was carried out using Agilent 1100 system: an analytical column, ODS (5 μm , 4.6 \times 250 mm, Agela, Tianjin, China); preparative column, an Agela Venusil XBP C18 (5 μm , 10.0 \times 250 mm, Agela); Shodex RID 102 detector (Showa Denko Group, Tokyo, Japan); and Alltech evaporative light scattering detector (ELSD) (evaporative light-scattering detector) 2100.

3.2 Plant material

The rhizomes of *A. typica* were harvested from Xishuangbanna, Yunnan Province, China in August 2011, and identified by Prof. Li-xia Zhang (Yunnan Branch of Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences). A voucher specimen (No. 110820) has been deposited in the Herbarium of Beijing Institute of Radiation Medicine, Beijing.

3.3 Extraction and isolation

The air-dried rhizome slices of *A. typica* (2.0 kg) were extracted with 60% EtOH–

H₂O for three times (2 h each time) by reflux. The combined extracts were evaporated to about 2 liters under reduced pressure and the condensate was extracted with isovolumetric *n*-BuOH for three times. After removing the solvent from the *n*-BuOH layer by concentrating and freeze drying, the powder of total saponin (92.0 g) was obtained. It was initially separated by a silica gel and eluted with a gradient mixture of CHCl₃–MeOH (3:1, 2:1, 1:1) to give five fractions (A–E).

A part of fraction D (7.9 g) was subjected to MCI CHP20/P50 column chromatography and eluted with 30% EtOH–H₂O to produce 14 subfractions (D₁–D₁₄). Fraction D₁ (1.12 g) was chromatographed on an ODS silica gel column with a gradient mixture of MeOH–H₂O (3:7, 7:13, 2:3, 9:11, and 8:2; 50 ml each tube) as eluent. A total of 150 tubes were collected. Then, tubes 74–86 (94 mg) were combined and further isolated by semi-preparative HPLC (column: 10 \times 250 mm, RP-18, 5 μm) with MeOH–H₂O (41:59, 4.0 ml/min) to give compound **1** (34.9 mg, t_{R} = 42.9 min) and compound **2** (15.3 mg, t_{R} = 39.4 min). A part of fraction D₆ (128.6 mg) was purified by semi-preparative HPLC with ACN–H₂O (27:73, 4.0 ml/min) to afford compound **3** (80.9 mg, t_{R} = 21.6 min).

3.3.1 Compound 1

White amorphous solid; $[\alpha]_{\text{D}}^{20}$ –62.5 (*c* 0.080, pyridine). IR (KBr) ν_{max} : 3413, 2931, 1706, 1647, 1377, and 1073 cm^{-1} . ^1H NMR (pyridine- d_5 , 599.8 MHz) and ^{13}C NMR (pyridine- d_5 , 150.8 MHz) spectral data, see Table 1. ESI-MS (neg.): m/z 1093 [M–H–132][–], 1063 [M–H–162][–], 931 [M–H–132–162][–], 751 [M–H–132–162–180][–], 589 [M–H–132–162–162–180][–], and 427 [M–H–132–162–162–180–162][–]. HR-ESI-MS (neg.): m/z 1225.5457 [M–H][–] (calcd for C₅₆H₈₉O₂₉, 1225.5490).

Table 1. ¹H and ¹³C NMR spectral data of compounds **1** and **2** (δ in pyridine-*d*₅).

Position	1		2	
	δ_C	$\delta_H J$ (Hz)	δ_C	$\delta_H J$ (Hz)
1	37.0	0.85 m, 1.45 o ^a	37.0	0.85 m, 1.45 o
2	29.9	1.62 m, 2.03 o	29.9	1.63 m, 2.03 o
3	77.9	3.82 m	77.9	3.82 m
4	39.1	2.37 m, 2.65 m	39.1	2.37 m, 2.65 m
5	140.8	–	140.8	–
6	121.4	5.25 br s	121.3	5.25 br s
7	31.8	1.44 o, 1.85 m	31.8	1.45 o, 1.84 m
8	30.9	1.83 m	30.9	1.83 m
9	52.3	1.28 m	52.3	1.28 m
10	37.6	–	37.6	–
11	37.6	2.27 dd (5.7, 14.5), 2.51 dd (13.3, 14.5)	37.6	2.27 dd (5.6, 14.7), 2.51 m
12	212.8	–	212.8	–
13	55.3	–	55.3	–
14	55.9	1.40 o	55.9	1.40 o
15	31.8	1.60 m, 2.06 m	32.7	1.59 m, 2.06 m
16	79.7	4.86 o	79.7	4.85 o
17	54.8	2.93 dd (6.8, 8.4)	54.8	2.92 dd (6.8, 8.6)
18	16.1	1.14 s	16.1	1.13 s
19	18.8	0.89 s	18.8	0.89 s
20	41.3	2.19 m	41.3	2.19 m
21	15.2	1.53 d (6.6)	15.2	1.52 d (6.6)
22	110.8	–	110.8	–
23	37.1	2.03 o	37.1	1.95 m, 2.05 o
24	28.4	1.66 m, 2.03 o	28.4	1.67 m, 2.04 o
25	34.3	1.91 m	34.4	1.92 m
26	75.3	3.60 dd (6.0, 9.6), 3.94 o	75.4	3.49 dd (6.9, 9.3), 4.07 o
27	17.4	0.97 d (7.2)	17.5	1.02 d (7.2)
Sugar part				
Glc3				
1	105.0	4.80 d (7.8)	105.2	4.80 d (7.8)
2	75.2	4.01 t (7.8)	75.2	4.01 t (7.8)
3	78.6	4.22 o	78.7	4.23 o
4	71.8	4.22 o	71.7	4.22 o
5	78.5	3.93 o	78.5	3.93 o
6	62.9	4.37 o, 4.54 o	62.9	4.37 o, 4.53 o
Gal				
1	102.8	4.86 d (7.8)	102.8	4.86 d (7.8)
2	73.2	4.41 o	72.5	4.40 o
3	75.6	4.09 o	75.6	4.08 o
4	79.9	4.58 o	79.9	4.58 o
5	75.4	3.95 o	75.3	3.95 o
6	60.6	4.16 o, 4.65 m	60.6	4.16 o, 4.65 m
Xyl				
1	105.0	5.22 d (7.8)	105.0	5.23 d (7.8)
2	75.1	3.95 o	75.1	3.95 o
3	78.7	4.06 o	78.7	4.07 o
4	70.8	4.09 o	70.8	4.10 o
5	67.4	3.66 t (10.5), 4.21 o	67.4	3.66 t (10.6), 4.21 o
Glc1				
1	105.2	5.18 d (8.4)	105.2	5.18 d (8.4)
2	81.4	4.42 t (8.4)	81.4	4.42 t (8.4)
3	86.8	4.16 o	86.8	4.16 o
4	70.5	3.81 m	70.5	3.80 m

Table 1 – continued

Position	1		2	
	δ_C	$\delta_H J$ (Hz)	δ_C	$\delta_H J$ (Hz)
5	77.6	3.87 m	77.6	3.87 m
6	63.0	4.04 o, 4.50 m	63.0	4.03 o, 4.51 o
Glc2			Glc2	
1	104.9	5.57 d (7.8)	104.9	5.57 d (7.8)
2	76.2	4.06 o	76.3	4.06 o
3	77.7	4.11 o	77.8	4.11 o
4	71.1	4.19 o	71.1	4.19 o
5	78.8	3.92 o	78.8	3.92 o
6	62.5	4.36o, 4.56 o	62.5	4.36 o, 4.56 o

^a Overlapped with other signals.

3.3.2 Compound 2

White amorphous solid; $[\alpha]_D^{20} - 53.3$ (c 0.060, pyridine). IR (KBr) ν_{\max} : 3420, 2931, 1707, 1646, 1377, and 1073 cm^{-1} . ¹H NMR (pyridine-*d*₅, 599.8 MHz), and ¹³C NMR (pyridine-*d*₅, 150.8 MHz) spectral data, see Table 1. ESI-MS (neg.): *m/z* 1093 [M–H–132][–], 1063 [M–H–162][–], 931 [M–H–132–162][–], 751 [M–H–132–162–180][–], 589 [M–H–132–162–162–180][–], and 427 [M–H–132–162–162–180–162][–]. HR-ESI-MS (neg.): *m/z* 1225.5453 [M–H][–] (calcd for C₅₆H₈₉O₂₉, 1225.5490).

3.4 Acid hydrolysis of compounds 1 and 2

Compounds **1** (2.7 mg) and **2** (2.2 mg) were separately treated with 2N aq. CF₃COOH (5 ml) at 95°C for 2.5 h. The cooled hydrolysate was extracted with CH₂Cl₂ (5 ml) for three times. The aqueous phase was concentrated to dryness with EtOH to yield the sugar residue. Then it was dissolved in anhydrous pyridine (2 ml), and L-cysteine methyl ester hydrochloride (12 mg) was added. The mixture was stirred at 60°C for 1 h. Furthermore, (hexamethyldisilazane–trimethylchlorosilane, 2:1; 6 ml) was added and preserved at 60°C for another 0.5 h [19]. In the end, the supernatant was

analyzed by GC under the following conditions: Agilent Technologies 6890 gas chromatograph equipment; 5973 mass spectrograph detector; HP-5 capillary column (30 m × 0.25 mm × 0.25 μm); column temperature: 180°C–250°C, programmed increase, 15°C/min; carrier gas: N₂ (1 ml/min); injection and detector temperature: 250°C; injection volume: 1.0 μl; split ratio: 1/50. Ultimately, the D-configurations of glucose, galactose, and xylose were determined by comparing their retention times with those of standard samples, respectively. *t*_R: D-glucose (17.93, 19.67 min), D-xylose (13.01, 14.77 min), and D-galactose (18.54, 20.24 min).

Acknowledgments

This investigation was financially supported by the Major Program of Municipal Natural Science Foundation of Beijing (7090001). The authors are grateful to Miss Mei-Feng Xu of the National Center of Biomedical Analysis for measurements of the NMR spectra.

References

- [1] M.J. Chen, *Chin. Bull. Bot.* **16**, 37 (1999).
- [2] Y.G. Wei, G.Z. Li, K.Y. Lang, and R.X. Wang, *Guihaia* **20**, 218 (2000).
- [3] Y. Mori and T. Kawasaki, *Chem. Pharm. Bull.* **21**, 224 (1973).

- [4] Y. Hirai, T. Konishi, S. Sanada, Y. Ida, and J. Shoji, *Chem. Pharm. Bull.* **30**, 3476 (1982).
- [5] T. Konishi, S. Kiyosawa, and J. Shoji, *Chem. Pharm. Bull.* **32**, 1451 (1984).
- [6] M.J. Chen, G.Q. Xiang, and G.W. Zhang, *Acta Bot. Sin.* **32**, 297 (1990).
- [7] C.X. Chen and J. Zhou, *Acta Bot. Yunnan.* **16**, 397 (1994).
- [8] M.J. Chen, *Acta Bot. Sin.* **36**, 568 (1994).
- [9] M.J. Chen, *Nat. Prod. Res. Dev.* **7**, 19 (1995).
- [10] M.J. Chen and S.Y. Liang, *Chin. Bull. Bot.* **16**, 610 (1999).
- [11] Q.X. Yang and C.R. Yang, *Acta Bot. Yunnan.* **22**, 109 (2000).
- [12] H.S. Wang, M.X. Tan, C.S. Gong, W.S. Chen, S. Li, and G.Z. Li, *Guihaia* **23**, 450 (2003).
- [13] Z.Y. Meng, S.X. Xu, W. Li, and Y. Sha, *Chin. J. Med. Chem.* **9**, 294 (1999).
- [14] P.K. Agrawal, *Phytochemistry* **31**, 3307 (1992).
- [15] E. Fattorusso, M. Iorizzi, V. Lanzotti, and O. Targliatela-Scafati, *J. Agric. Food Chem.* **50**, 5686 (2002).
- [16] P.K. Agrawal, *Steroids* **70**, 715 (2005).
- [17] M.H.A. Elgamal, M.S. Bedour, and H. Duddeck, *Indian J. Chem.* **19**, 549 (1980).
- [18] J. Zhang, B.P. Ma, L.P. Kang, H.S. Yu, Y. Yang, X.Z. Yan, and F.T. Dong, *Chem. Pharm. Bull.* **54**, 931 (2006).
- [19] A.C. Mitaine-Offer, N. Pérez, T. Miyamoto, C. Delaude, J.F. Mirjolet, O. Duchamp, and M.A. Lacaille-Dubois, *Phytochemistry* **71**, 90 (2010).